ANI Pharmaceuticals Inc. Highlights Strong Revenue and EBITDA Growth in Latest Corporate Presentation

Reuters

2025/11/10

ANI Pharmaceuticals Inc. Highlights Strong Revenue and EBITDA Growth in Latest Corporate Presentation

ANI Pharmaceuticals Inc. has released a new corporate presentation outlining its financial performance and future outlook. The company reported a significant increase in total net revenues, projecting $854-$873 million for 2025, up from $614 million in 2024, representing an estimated 39-42% growth. Adjusted non-GAAP EBITDA is expected to rise to $221-$228 million in 2025 from $156 million in 2024, indicating a 42-46% increase. The presentation also notes the FDA approval to add the NIU-PS indication to ILUVIEN in the U.S., with commercialization efforts for ILUVIEN and YUTIQ consolidated under the ILUVIEN brand as of June 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582058874"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582058874\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582058874?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582058874","market":"nz","top_or_hot":-1,"title":"ANI Pharmaceuticals Inc. Highlights Strong Revenue and EBITDA Growth in Latest Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ANI Pharmaceuticals Inc. Highlights Strong Revenue and EBITDA Growth in Latest Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ANI Pharmaceuticals Inc. has released a new corporate presentation outlining its financial performance and future outlook. The company reported a significant increase in total net revenues, projecting $854-$873 million for 2025, up from $614 million in 2024, representing an estimated 39-42% growth. Adjusted non-GAAP EBITDA is expected to rise to $221-$228 million in 2025 from $156 million in 2024, indicating a 42-46% increase. The presentation also notes the FDA approval to add the NIU-PS indication to ILUVIEN in the U.S., with commercialization efforts for ILUVIEN and YUTIQ consolidated under the ILUVIEN brand as of June 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ANI Pharmaceuticals Inc. Highlights Strong Revenue and EBITDA Growth in Latest Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nANI Pharmaceuticals Inc. Highlights Strong Revenue and EBITDA Growth in Latest Corporate Presentation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 21:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ANI Pharmaceuticals Inc. Highlights Strong Revenue and EBITDA Growth in Latest Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ANI Pharmaceuticals Inc. has released a new corporate presentation outlining its financial performance and future outlook. The company reported a significant increase in total net revenues, projecting $854-$873 million for 2025, up from $614 million in 2024, representing an estimated 39-42% growth. Adjusted non-GAAP EBITDA is expected to rise to $221-$228 million in 2025 from $156 million in 2024, indicating a 42-46% increase. The presentation also notes the FDA approval to add the NIU-PS indication to ILUVIEN in the U.S., with commercialization efforts for ILUVIEN and YUTIQ consolidated under the ILUVIEN brand as of June 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1rXkM7:1","article_id":"2582058874","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582058874","pubTimestamp":1762782973,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ANI Pharmaceuticals Inc. has released a new corporate presentation outlining its financial performance and future outlook. The company reported a significant increase in total net revenues, projecting $854-$873 million for 2025, up from $614 million in 2024, representing an estimated 39-42% growth. Adjusted non-GAAP EBITDA is expected to rise to $221-$228 million in 2025 from $156 million in 2024, indicating a 42-46% increase. The presentation also notes the FDA approval to add the NIU-PS indication to ILUVIEN in the U.S., with commercialization efforts for ILUVIEN and YUTIQ consolidated under the ILUVIEN brand as of June 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc.","LU0566484027.USD":"安本美国小盘成长股","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药"},"translate_title":"ANI Pharmaceuticals Inc.在最新的公司演示中强调了强劲的收入和EBITDA增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":0.9},"content_text":"ANI Pharmaceuticals Inc. Highlights Strong Revenue and EBITDA Growth in Latest Corporate Presentation\n    \n\n        ANI Pharmaceuticals Inc. has released a new corporate presentation outlining its financial performance and future outlook. The company reported a significant increase in total net revenues, projecting $854-$873 million for 2025, up from $614 million in 2024, representing an estimated 39-42% growth. Adjusted non-GAAP EBITDA is expected to rise to $221-$228 million in 2025 from $156 million in 2024, indicating a 42-46% increase. The presentation also notes the FDA approval to add the NIU-PS indication to ILUVIEN in the U.S., with commercialization efforts for ILUVIEN and YUTIQ consolidated under the ILUVIEN brand as of June 2025. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}